NeoGenomics, Inc. (NEO): Price and Financial Metrics


NeoGenomics, Inc. (NEO)

Today's Latest Price: $27.01 USD

0.60 (-2.17%)

Updated Apr 1 10:30am

Add NEO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

NEO Stock Summary

  • NEO's current price/earnings ratio is 354.2, which is higher than 99.02% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for NEO is currently 121.34, higher than 98.02% of US stocks with positive operating cash flow.
  • Revenue growth over the past 12 months for Neogenomics Inc comes in at 47.73%, a number that bests 88.79% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Neogenomics Inc are CRY, MMSI, BYFC, INFU, and ENR.
  • Visit NEO's SEC page to see the company's official filings. To visit the company's web site, go to www.neogenomics.com.
NEO Daily Price Range
NEO 52-Week Price Range

NEO Stock Price Chart More Charts


NEO Price/Volume Stats

Current price $27.01 52-week high $34.97
Prev. close $27.61 52-week low $18.52
Day low $26.50 Volume 69,633
Day high $27.69 Avg. volume 957,164
50-day MA $29.70 Dividend yield N/A
200-day MA $25.57 Market Cap 2.83B

NeoGenomics, Inc. (NEO) Company Bio


NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.

NEO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$27.01$0.26-99%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Neogenomics Inc. To summarize, we found that Neogenomics Inc ranked in the 3th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Neogenomics Inc, consider:

  • The compound growth rate in the free cash flow of Neogenomics Inc over the past 5.59 years is -0.01%; that's better than only 21.41% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately only 11.92% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Neogenomics Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-99%
1%-99%
2%-99%
3%-99%
4%-99%
5%-99%

Want more companies with a valuation profile/forecast similar to that of Neogenomics Inc? See ALC, AMPH, ARA, CSII, and ELAN.


NEO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NEO Latest Social Stream


Loading social stream, please wait...

View Full NEO Social Stream

NEO Price Returns

1-mo -8.38%
3-mo -7.02%
6-mo 35.66%
1-year 30.86%
3-year 242.33%
5-year 463.88%
YTD -7.66%
2019 131.96%
2018 42.33%
2017 3.38%
2016 8.89%
2015 88.73%

Continue Researching NEO

Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:

Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7451 seconds.